Overview
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Eligibility
Inclusion Criteria:
- Participant aged 18 years or older
- Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
- Participant newly initiated deucravacitinib according to the label
- Provided written informed consent to participate in the study
Exclusion Criteria:
- Participating in or planning to participate in an interventional clinical trial
- Concomitant use of other systemic treatments for psoriasis at baseline
- Prior treatment of deucravacitinib